About
General Control Biotechnologies develops programmable multiplexed epigenetic editors to coordinately control multiple genes in order to treat complex age-related diseases such as Alzheimer's and sarcopenia by rewriting gene expression to healthy baselines.
Explore General Control Biotechnologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.